Cancelled due to lack of patient A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases

A randomized controlled study to evaluate the efficacy and safety of hydroxychloroquine for mild and moderate COVID-19 Infectious diseases

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029760

Enrollment

Unknown

Registered

2020-02-12

Start date

2020-02-12

Completion date

Unknown

Last updated

2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Experimental group:Hydroxychloroquin

Control group:Lopinavir /Ritonavir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Informed consent offered; 2. Confirmed infection with 2019-nCoV by RT-PCR; 3. Compliance with the intervention of study.

Exclusion criteria

Exclusion criteria: 1. Known allergic to hydroxychloroquine or 4-aminoquinoline; 2. Severe renal impairment (eGFR = C, AST>5 times upper limit); 4. Pre-existing retinopathy of the eye; 5. History of epilepsy; 6. G6PD deficiency; 7. Pregnant or breastfeeding; 8. Patients taking tamoxifen; 9. The study not in patients' best interests judged by the physician.

Design outcomes

Primary

Measure	Time frame
Time to clinical recovery;	—

Secondary

Measure	Time frame
Time to defervescence;Time to absence of 2019-nCoV;Time to normalization of inflammation markers;Time to normalization of respiratory rate;Time to normalization of cough;Duration of hospitalization;Frequency of lung radiologic improvement;Frequency of respiratory progression;Frequency of ICU admission;All-cause mortality;Frequency of adverse events;	—

Countries

China

Contacts

Public ContactHuawei Mao

Chongqing Medical University

maohwei@qq.com+86 13928459556

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026